Regulus Therapeutics Inc
RGLS7.980USD
+4.610+136.80%
收盘 04/30, 16:00（美东）报价延迟15分钟
522.69M总市值
亏损市盈率 TTM
关于 Regulus Therapeutics Inc 公司
Regulus Therapeutics Inc. 是一家临床阶段的生物制药公司。该公司专注于发现和开发针对 microRNA 的药物，以治疗具有重大未满足医疗需求的疾病。该公司专注于孤儿肾病，这些疾病涉及 microRNA 遗传驱动因素，并且存在明显未满足的医疗需求。其候选产品 RGLS8429 是一种针对 miR-17 的抗 miR 下一代寡核苷酸，用于治疗常染色体显性多囊肾病 (ADPKD)，目前处于 1b 期临床开发阶段。除了这个项目之外，该公司还继续推进和扩展其内部发现渠道，以确定潜在的候选产品。microRNA 是天然存在的核糖核酸 (RNA) 分子，在调节关键生物途径方面发挥着关键作用。ADPKD 是常见的人类单基因疾病之一，也是终末期肾病的病因。
公司简介
公司代码RGLS
公司名称Regulus Therapeutics Inc
上市日期Oct 04, 2012
成立日期2007
CEOMr. Joseph P. (Jay) Hagan
员工数量34
证券类型Ordinary Share
年结日Oct 04
公司地址4224 Campus Point Court
城市SAN DIEGO
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编92121
电话18582026300
网址https://www.regulusrx.com/
公司代码RGLS
上市日期Oct 04, 2012
成立日期2007
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Stelios B. Papadopoulos, Ph.D.
Dr. Stelios B. Papadopoulos, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
978.39K
+75.85%
Mr. Christopher Ray Aker, J.D.
Mr. Christopher Ray Aker, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
50.55K
+402.65%
Ms. Crispina Calsada, CPA
Ms. Crispina Calsada, CPA
Chief Financial Officer
Chief Financial Officer
45.48K
+686.54%
Dr. William H. (Bill) Rastetter, Ph.D.
Dr. William H. (Bill) Rastetter, Ph.D.
Independent Director
Independent Director
39.06K
--
Mr. Preston S. Klassen, M.D.
Mr. Preston S. Klassen, M.D.
President, Head of Research & Development, Director
President, Head of Research & Development, Director
36.05K
--
Dr. David Baltimore, Ph.D.
Dr. David Baltimore, Ph.D.
Independent Director
Independent Director
22.17K
+766.31%
Ms. Pascale Witz
Ms. Pascale Witz
Independent Director
Independent Director
4.73K
--
Mr. Joseph P. (Jay) Hagan
Mr. Joseph P. (Jay) Hagan
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Rekha Garg
Ms. Rekha Garg
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Jake R. Nunn
Mr. Jake R. Nunn
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Stelios B. Papadopoulos, Ph.D.
Dr. Stelios B. Papadopoulos, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
978.39K
+75.85%
Mr. Christopher Ray Aker, J.D.
Mr. Christopher Ray Aker, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
50.55K
+402.65%
Ms. Crispina Calsada, CPA
Ms. Crispina Calsada, CPA
Chief Financial Officer
Chief Financial Officer
45.48K
+686.54%
Dr. William H. (Bill) Rastetter, Ph.D.
Dr. William H. (Bill) Rastetter, Ph.D.
Independent Director
Independent Director
39.06K
--
Mr. Preston S. Klassen, M.D.
Mr. Preston S. Klassen, M.D.
President, Head of Research & Development, Director
President, Head of Research & Development, Director
36.05K
--
Dr. David Baltimore, Ph.D.
Dr. David Baltimore, Ph.D.
Independent Director
Independent Director
22.17K
+766.31%
收入明细
FY2021
FY2020
FY2019
暂无数据
地区USD
名称
营收
占比
United States
0.00
0.00%
业务
地区
暂无数据
股东统计
更新时间: 2月23日 周日
更新时间: 2月23日 周日
持股股东
股东类型
持股股东
股东统计
占比
Federated Hermes Global Investment Management Corp.
19.40%
New Enterprise Associates (NEA)
9.76%
Vivo Capital, LLC
7.55%
Octagon Capital Advisors LP
7.32%
The Vanguard Group, Inc.
5.99%
Other
49.98%
持股股东
股东统计
占比
Federated Hermes Global Investment Management Corp.
19.40%
New Enterprise Associates (NEA)
9.76%
Vivo Capital, LLC
7.55%
Octagon Capital Advisors LP
7.32%
The Vanguard Group, Inc.
5.99%
Other
49.98%
股东类型
股东统计
占比
Investment Advisor/Hedge Fund
32.76%
Hedge Fund
27.99%
Venture Capital
17.31%
Investment Advisor
7.47%
Individual Investor
2.18%
Research Firm
0.97%
Bank and Trust
0.11%
Pension Fund
0.08%
Other
11.13%
机构持股
更新时间: 3月4日 周二
更新时间: 3月4日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q1
137
56.08M
84.66%
-6.18M
2024Q4
137
55.74M
85.10%
-6.54M
2024Q3
128
58.95M
90.05%
-6.89M
2024Q2
113
63.43M
96.89%
+3.08M
2024Q1
85
60.55M
95.51%
+47.86M
2023Q4
70
12.67M
62.78%
-270.56K
2023Q3
77
12.73M
68.68%
-335.94K
2023Q2
80
12.00M
64.97%
-983.27K
2023Q1
89
9.82M
61.73%
-1.56M
2022Q4
92
9.90M
62.22%
-2.24M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Federated Hermes Global Investment Management Corp.
12.85M
19.4%
--
--
Dec 31, 2024
New Enterprise Associates (NEA)
6.47M
9.76%
--
--
Dec 31, 2024
Vivo Capital, LLC
5.00M
7.55%
--
--
Dec 31, 2024
Octagon Capital Advisors LP
4.85M
7.32%
+585.10K
+13.72%
Dec 31, 2024
The Vanguard Group, Inc.
3.97M
5.99%
-121.67K
-2.98%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
3.89M
5.88%
+146.29K
+3.90%
Dec 31, 2024
Point72 Asset Management, L.P.
895.13K
1.35%
+1.37K
+0.15%
Dec 31, 2024
Deep Track Capital LP
3.26M
4.93%
--
--
Dec 31, 2024
Millennium Management LLC
2.19M
3.31%
+900.74K
+69.75%
Dec 31, 2024
Adage Capital Management, L.P.
2.00M
3.02%
--
--
Dec 31, 2024
查看更多
持股ETF
更新时间: 4月6日 周日
更新时间: 4月6日 周日
机构名称
占比
iShares Micro-Cap ETF
0.02%
iShares Russell 2000 Value ETF
0.01%
Global X Russell 2000 ETF
0%
iShares Russell 2000 ETF
0%
iShares Russell 2000 Growth ETF
0%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Avantis US Small Cap Equity ETF
0%
Proshares Ultra Russell 2000
0%
iShares Micro-Cap ETF
占比0.02%
iShares Russell 2000 Value ETF
占比0.01%
Global X Russell 2000 ETF
占比0%
iShares Russell 2000 ETF
占比0%
iShares Russell 2000 Growth ETF
占比0%
ProShares UltraPro Russell2000
占比0%
ProShares Hedge Replication ETF
占比0%
iShares Core S&P Total U.S. Stock Market ETF
占比0%
Avantis US Small Cap Equity ETF
占比0%
Proshares Ultra Russell 2000
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Jun 28, 2022
Merger
10<1
Jun 28, 2022
Merger
10<1
Jun 28, 2022
Merger
10<1
Jun 28, 2022
Merger
10<1
公告日期
类型
比率
Jun 28, 2022
Merger
10<1
Jun 28, 2022
Merger
10<1
Jun 28, 2022
Merger
10<1
Jun 28, 2022
Merger
10<1